How We Invest

13F FILER

Novo Holdings

Novo Holdings A/S

No writing by this manager has been read and indexed yet, so this page carries the filings only. Holdings come straight from the Form 13F-HR on EDGAR.

25

Positions

$1.7B

Reported Value

73.5%

In Top 10

—

Claims Indexed

Largest reported positions

NOVO HOLDINGS A/S • CIK 0001388325 • 2026-06-30 • FILED 2026-08-14

WHAT CHANGED THIS QUARTER

In its Q2 2026 13F, filed Aug 14, 2026, Novo Holdings reported 25 positions worth $1.7B in US-listed stock. The largest stock position is Edgewise Therapeutics Inc at 12.6% of the reported book, and the ten largest lines of any type make up 73.5% of it.

It opened 6 new positions, the largest stock positions being Hemab Therapeutics Hldgs Inc ($153.6M), Avalyn Pharmaceuticals Inc ($127.8M) and Floor & Decor Hldgs Inc ($47.3M), and exited 3, the largest stock exits being Apogee Therapeutics Inc ($37.9M last quarter), Biomarin Pharmaceutical Inc ($37.3M last quarter) and Valneva Se ($6.6M last quarter).

Among positions it already held, the biggest increases by share count were Viridian Therapeutics Inc (+7%) and Bridgebio Oncology Therapeut (+3%), and the biggest cuts were Arrivent Biopharma Inc (−23%), Enliven Therapeutics Inc (−22%) and Pharvaris N V (−20%).

Largest reported positions, quarter ended 2026-06-30
IssuerValueWeightShares QoQ
EDGEWISE THERAPEUTICS INC$217.4M12.6%—
ASML HOLDING N V$188.9M11.0%—
HEMAB THERAPEUTICS HLDGS INC$153.6M8.9%New
BROOKFIELD CORP$149.5M8.7%—
MAPLIGHT THERAPEUTICS INC$132.1M7.7%—
MIRUM PHARMACEUTICALS INC$131.7M7.7%-15%
AVALYN PHARMACEUTICALS INC$127.8M7.4%New
SALESFORCE INC$61.6M3.6%—
ARRIVENT BIOPHARMA INC$52.1M3.0%-23%
ENLIVEN THERAPEUTICS INC$50.8M3.0%-22%
CRINETICS PHARMACEUTICALS IN$49.4M2.9%-15%
PHARVARIS N V$48.4M2.8%-20%
FLOOR & DECOR HLDGS INC$47.3M2.8%New
VAXCYTE INC$46.5M2.7%-7%
4D MOLECULAR THERAPEUTICS IN$43.2M2.5%-11%
VIRIDIAN THERAPEUTICS INC$39.2M2.3%+7%
CELLDEX THERAPEUTICS INC NEW$38.1M2.2%-15%
ALUMIS INC$31.0M1.8%New
XENON PHARMACEUTICALS INC$29.3M1.7%—
ALIBABA GROUP HLDG LTD$24.7M1.4%—

20 of 25 positions. A 13F covers long US-listed positions at a quarter end only — no shorts, leverage, cash, ordinary bonds or private holdings — and is 45 days old on publication.

NEW POSITIONS

  • Hemab Therapeutics Hldgs Inc$153.6M · 8.9%
  • Avalyn Pharmaceuticals Inc$127.8M · 7.4%
  • Floor & Decor Hldgs Inc$47.3M · 2.8%
  • Alumis Inc$31.0M · 1.8%
  • Dyne Therapeutics Inc$21.3M · 1.2%

EXITS

  • Apogee Therapeutics Inc$37.9M last quarter
  • Biomarin Pharmaceutical Inc$37.3M last quarter
  • Valneva Se$6.6M last quarter

QUESTIONS PEOPLE ASK

What are Novo Holdings' largest holdings?

OPEN
As of Jun 30, 2026, the three largest stock positions are Edgewise Therapeutics Inc (12.6%), Asml Holding N V (11.0%) and Hemab Therapeutics Hldgs Inc (8.9%), together 32.5% of the reported book.

How big is Novo Holdings' 13F portfolio?

OPEN
The Q2 2026 13F, filed Aug 14, 2026, reports 25 positions worth $1.7B. The ten largest make up 73.5% of it.

What did Novo Holdings buy and sell in Q2 2026?

OPEN
It opened 6 new positions, the largest stock positions being Hemab Therapeutics Hldgs Inc ($153.6M), Avalyn Pharmaceuticals Inc ($127.8M) and Floor & Decor Hldgs Inc ($47.3M), and exited 3, the largest stock exits being Apogee Therapeutics Inc ($37.9M last quarter), Biomarin Pharmaceutical Inc ($37.3M last quarter) and Valneva Se ($6.6M last quarter). Among positions it already held, the biggest increases by share count were Viridian Therapeutics Inc (+7%) and Bridgebio Oncology Therapeut (+3%), and the biggest cuts were Arrivent Biopharma Inc (−23%), Enliven Therapeutics Inc (−22%) and Pharvaris N V (−20%).

When is Novo Holdings' next 13F due?

OPEN
The Q3 2026 13F is due Nov 16, 2026. Forty-five days after the quarter ends is November 14, 2026 (Saturday), so the deadline moves to the next business day.

Filers with overlapping books